Abstract | OBJECTIVE: this prospective cohort study aimed to assess the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. METHODS: in this study, 40 Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer selected to receive bevacizumab with chemotherapy were enrolled. Patients in poor general condition were excluded. Each patient was monitored prospectively for adverse events, administration status, disease status and survival. Treatment was continued until intolerable adverse events or disease progression. The primary endpoint was safety. RESULTS: CONCLUSION:
|
Authors | Yoshiko Nanki, Hiroyuki Nomura, Naomi Iwasa, Keiko Saotome, Ai Dozen, Tomoko Yoshihama, Takuro Hirano, Shiho Hashimoto, Tatsuyuki Chiyoda, Wataru Yamagami, Fumio Kataoka, Daisuke Aoki |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 51
Issue 1
Pg. 54-59
(Jan 01 2021)
ISSN: 1465-3621 [Electronic] England |
PMID | 32776094
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Bevacizumab
(administration & dosage, adverse effects)
- Fallopian Tube Neoplasms
(drug therapy, mortality)
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy, mortality)
- Peritoneal Neoplasms
(drug therapy, mortality)
- Prospective Studies
|